Literatur
- 1
Antman E M.
Dose-ranging trial of enoxaparin for unstable angina: results
of TIMI 11A.
J Am Coll
Cardiol.
1997;
29
1474-1482
- 2
Antman E M, Cohen M, Radley D. et al. for the TIMI 11B (Thrombolysis in Myocardial
Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in
Non-Q-wave Coronary Events) Investigators .
Assessment of the treatment effect of enoxaparin for unstable
angina/non-Q-wave myocardial
infarction.
Circulation.
1999;
100
1602-1608
- 3
Antman E M, McCabe C H, Gurfinkel E P. et al. for the TIMI 11B Investigators .
Enoxaparin prevents death and cardiac ischemic events in
unstable angina/non-Q-wave myocardial infarction. Results of Thrombolysis
in Myocardial Infarction (TIMI) 11B
Trial.
Circulation.
1999;
100
1593-1601
- 4
Antman E M.
The search for replacements for unfractionated
heparin.
Circulation.
2001;
103
2310-2314
- 5
The Assessment of the safety and efficacy of a new
thrombolytic regimen (ASSENT)-3 investigators .
Efficacy and safety of tenecteplase in combination with
enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial
in acute myocardial
infarction.
Lancet.
2001;
358
605-613
- 6
Becker R C, Ball S P, Eisenberg P. et al .
A randomized, multicenter trial of weight-adjusted
intravenous heparin dose titration and point-of-care coagulation monitoring
in
hospitalized patients with active thromboembolic disease. Antithrombotic
therapy consortium investigators.
Am Heart
J.
1999;
137
59-71
- 7
Bertrand M E, Simoons M L, Fox K AA. et al .
Management of acute coronary syndromes: acute coronary
syndromes without persistent ST segment elevation.
Eur Heart
J.
2000;
21
1406-1432
- 8
Braunwald E.
Management of unstable angina based on considerations of
aetiology.
Heart.
1999;
82
(Suppl
I)
15-17
- 9
Braunwald E, Antman E M, Beasley J W. et al .
ACC/AHA Guidelines for the management of patients with
unstable angina and non-ST-segment elevation myocardial infarction: executive
summary and
recommendations.
Circulation.
2000;
102
1193-1209
- 10 Carlsson J, Miketic S, Tebbe U. Heparin und niedermolekulare Heparine in der Therapie
akuter
koronarer Syndrome. München, Medikon
Verlag In: Schrader, J. (Hrsg.) Niedermolekulare Heparine
- Fragmin. 1.
Auflage 1995: 70-81
- 11
Cohen M, Demers C, Gurfinkel E P. et al. for the Efficacy and Safeety of Subcutaneous
Enoxaparin in Non-q-wave Coronary Events Study Group (ESSENCE) .
A comparison of low-molecular-weight heparin with
unfractionated heparin for unstable coronary artery disease.
N Engl J
Med.
1997;
337
447-452
- 12
Cohen M, Stinnett S S, Weatherley B D. et al .
Predictors of recurrent ischemic events and death in unstable
coronary artery disease after treatment with combination antithrombotic
therapy.
Am Heart
J.
2000;
139
962-970
- 13
Collet J P, Montalescot G, Lison L. et al .
Percutaneous coronary intervention after subcutaneous
enoxaparin pretreatment in patients with unstable angina
pectoris.
Circulation.
2001;
103
658-663
- 14
Collignon F, Frydman A, Caplain H. et al .
Comparison of the pharmacokinetic profiles of three low
molecular mass heparins - dalteparin, enoxaparin, and nadroparin -
administered subcutaneously in healthy volunteers (doses for prevention of
thromboembolism).
Thromb
Haemost.
1995;
73
630-640
- 15
Eikelbloom I W, Anand S S, Malmberg K, Weitz J I, Ginsberg J S, Yusuf S.
Unfractionated heparin and low-molecular-weight heparin in
acute coronary syndrome without ST-elevation: a
meta-analysis.
Lancet.
2000;
355
1936-1942
- 16
Fox K A, Goodman S, Bigonzi F, Le
Louer V, Cohen M.
Inter-regional differences and outcome in unstable angina;
analysis of the international ESSENCE trial. Efficacy and Safety of
Subcutaneous Enoxaparin in Non-Q-wave Coronary Events.
Eur Heart
J.
2000;
21
1433-1439
- 17
FRISC-Study Group. Fragmin during instability in Coronary
Artery Disease (FRISC) Study Group .
Low-molecular-weight heparin during instability in coronary
artery
disease.
Lancet.
1996;
347
561-568
- 18
FRISC-II-Study Group .
Invasive compared with non-invasive treatment in unstable
coronary-artery disease: FRISC II prospective randomised multicentre
study.
Lancet.
1999;
354
708-714
- 19
FRISC-II-Study Group .
Long-term low-molecular-mass heparin in unstable
coronary-artery disease: FRISC II prospective randomised multicentre
study.
Lancet.
1999;
354
701-707
- 20
Glick A, Kornowsky R, Michowich Y. et al .
Reduction of reinfarction and angina with use of
low-molecular-weight heparin therapy after streptokinase (and heparin) in acute
myocardial infarction.
Am J
Cardiol.
1996;
77
1145-1148
- 21
Goodman S G, Cohen M, Bigonzi F. et al .
Randomized trial of low molecular weight heparin (enoxaparin)
versus unfractionated heparin for unstable coronary artery disease: one-year
results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin
in
Non-Q Wave Coronary Events.
J Am Coll
Cardiol.
2000;
36
693-698
- 22
Goodman S G, Barr A, Sobtchouk A. et al .
Low molecular weight heparin decreases rebound ischemia in
unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE S
segment monitoring substudy.
J Am Coll
Cardiol.
2000;
36
1507-1513
- 23
Goodman S G, Bozovich G, Tan M. et al .
The greatest benefit of enoxaparin (low molecular weight
heparin) over unfractionated heparin in acute coronary syndromes is achieved
in
patients presenting with ST segment
depression.
Circulation.
2001;
104
(Suppl
II)
549
- 24
Granger C B, Miller J M, Bovill E G. et al .
Rebound increase in thrombin generation and activity after
cessation of intravenous heparin in patients with acute coronary
syndromes.
Circulation.
1995;
91
1929-1935
- 25
Gurfinkel E, Manos E J, Mejail R I. et al .
Low molecular weight heparin versus regular heparin or
aspirin in the treatment of unstable angina and silent ischemia.
J Am
Coll
Cardiol.
1995;
26
313-318
- 26
Hamm C W, Braunwald E.
A classification of unstable angina
revisited.
Circulation.
2000;
102
118-122
- 27
Hamm C W, Bertrand M, Braunwald E.
Acute coronary syndrome without ST elevation: implementation
of new
guidelines.
Lancet.
2001;
358
1533-1538
- 28
Hirsh J, Levine M N.
Low molecular weight
heparin.
Blood.
1992;
79
1-17
- 29
Hirsh J, Fuster V.
Guide to anticoagulant therapy. Part 1:
Heparin.
Circulation.
1994;
89
1449-1468
- 30
Joint European Society of Cardiology/American College
of Cardiology Committee .
Myocardial infarction redefined: a consensus document of the
Joint European Society of Cardiology/American College of Cardiology
Committee for the redefinition of Myocardial infarction.
Eur Heart
J.
2000;
21
1502-1513
- 31
Kaul S, Shah K.
Low molecular weight heparin in acute coronary syndrome.
Evidence for superior or equivalent efficacy compared with unfractionated
heparin?.
J Am Coll
Cardiol.
2000;
35
1699-1712
- 32
Kereiakes D J, Grines C, Fry E. et al .
Enoxaparin and abciximab adjunctive pharmacotherapy during
percutaneous coronary intervention.
J Invasive
Cardiol.
2001;
13
272-278
- 33
Kereiakes D J, Kleiman N S, Fry E. et al .
Dalteparin in combination with abciximab during percutaneous
coronary intervention.
Am Heart
J.
2001;
141
348-352
- 34
Klein W, Buchwald A, Hillis S E. et al .
Comparison of low-molecular-weight heparin with
unfractionated heparin acutely and with placebo for 6 weeks in the management
of unstable coronary artery disease: the Fragmin in Unstable Coronary Artery
Disease Study
(FRIC).
Circulation.
1997;
95
61-68
- 35
Kontny F, Dale J, Abilgaard U. et al .
Randomized trial of low-molecular weight heparin (Dalteparin)
in prevention of left ventricular thrombus formation and arterial embolism
after acute anterior myocardial infarction. The Fragmin in Acute Myocardial
Infarction (FRAMI) Study.
J Am Coll
Cardiol.
1997;
30
962-969
- 36
Kovar D, Canto J G, Rogers W J.
Is low molecular weight heparin in combination with iv lytic
therapy safe and
effective?.
Circulation.
2001;
104
(Suppl
II)
88
- 37
Leizorovicz A. for the FRAX.I.S. Study Group .
Comparison of two treatment durations (6 days and 14 days) of
a low molecular weight heparin with a 6-day treatment of unfractionated heparin
in the initial management of unstable angina or non-Q-wave myocardial
infarction: FRAX.I.S. (Fraxiparine in Ischemic Syndrome).
Eur Heart
J.
1999;
20
1553-1562
- 38
Levine G N, Ali M N, Schafer A I.
Antithrombotic therapy in patients with acute coronary
syndromes.
Arch Intern
Med.
2001;
161
937-948
- 39
Lindahl B, Venge, P, Wallentin L. for the Fragmin in Unstable Coronary Artery Disease
(FRISC) Study Group .
Troponin T identifies patients with unstable coronary artery
disease who benefit from long-term antithrombotic protection.
J Am
Coll
Cardiol.
1997;
29
43-48
- 40
Mark D B, Cowper P A, Berkowitz S D. et al .
Economic assessment of low-molecular-weight heparin
(enoxaparin) versus unfractionated heparin in acute coronary syndrome patients.
Results from the ESSENCE randomized
trial.
Circulation.
1998;
97
1702-1707
- 41
McLean J.
The thromboplastic action of cephalin.
Am J
Physiol.
1916;
41
250-257
- 42
Montalesot G, Philippe F, Ankri A. et al. for the French Investigators of the ESSENCE
Trial .
Early increase of von Willebrand factor predicts adverse
outcome in unstable coronary artery disease. Beneficial effects of
enoxaparin.
Circulation.
1998;
98
294-299
- 43
O¿Brian B J, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S.
Will the use of low-molecular weight-heparin (enoxaparin) in
patients with acute coronary syndrome save costs in Canada?.
Am Heart
J.
2000;
139
423-429
- 44
Oler A, Whooley M A, Oler J, Grady D.
Adding heparin to aspirin reduces the incidence of myocardial
infarction and death in patients with unstable angina: a
meta-analysis.
J Am Med
Ass.
1996;
276
811-815
- 45
Ross A M, Molhoek P, Lundergan C. et al .
Randomized comparison of enoxaparin, a low-molecular-weight
heparin, with unfractionated heparin adjunctive to recombinant tissue
plasminogen activator thrombolysis and aspirin. Second trial of heparin and
aspirin reperfusion therapy (HART
II).
Circulation.
2001;
104
648-652
- 46
Theroux P, Waters D D, Lam J, Juneau M, McCans J.
Reactivation of unstable angina following discontinuation of
heparin.
N Engl J
Med.
1992;
327
141-145
- 47
Turpie A GG, Antman E M.
Low-molecular-weight heparins in the treatment of acute
coronary syndromes.
Arch Intern
Med.
2001;
161
1484-1490
- 48
Wallentin L, Lagerqvist B, Husted S. et al .
Outcome at 1 year after an invasive compared with a
non-invasive strategy in unstable coronary-artery disease: the FRISC II
invasive randomised
trial.
Lancet.
2000;
356
9-16
- 49
Wallentin L, Dellborg M, Lindahl B, Nilsson T, Pehrsson K, Swahn E.
The low-molecular-weight heparin dalteparin as adjuvant
therapy in acute myocardial infarction: the ASSENT PLUS study.
Clin
Cardiol.
2001;
24
(Suppl
I)
I12-I14
- 50
Warkentin T E, Levine M N, Hirsh J. et al .
Heparin-induced Thrombocytopenia in patients treated with
low-molecular-weight heparin or unfractionated heparin.
N Engl J
Med.
1995;
332
1330-1335
Priv.-Doz. Dr. med. Jörg Carlsson
Medizinische Klinik II
Klinikum Lippe-Detmold GmbH
Röntgenstraße 18
32756 Detmold
Phone: 05231/721185
Fax: 05231/721214
Email: Joerg.Carlsson@Klinikum-Lippe.de
